Sort
8,912 grants matching “sars cov 2”
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2
$649,870Gaya K. Amarasinghe · Washington University · R01 · FY2022 · AI
Neuroimaging Core
$649,560Peter Thornton Fox · University Of Texas Hlth Science Center · U19 · FY2025 · AG
Macaque Model and Gene Expression Profiling of SARS
$649,238Michael G Katze · University Of Washington · R01 · FY2006 · HL
Quantifying Error Growth to Improve Infectious Disease Forecast Accuracy
$649,085Jeffrey L Shaman · Columbia University Health Sciences · R01 · FY2023 · AI
Quantifying Error Growth to Improve Infectious Disease Forecast Accuracy
$649,085Jeffrey L Shaman · Columbia University Health Sciences · R01 · FY2022 · AI
Advancing understanding in the molecular mechanisms of viral epidemic potentiation
$648,935Nash Rochman · National Library Of Medicine · ZIA · FY2022 · LM
THE INFLUENZA VIRUS HAS BEEN RESPONSIBLE FOR SEVERAL PANDEMICS, AND HIGHLY PATHOGENIC AVIAN INFLUENZA (HPAI) VIRUSES REMAIN A SIGNIFICANT THREAT TO PUBLIC HEALTH. A RECENT SPILLOVER OF THE HPAI H5N1 VIRUS TO DAIRY COWS HAS LED TO HUMAN INFECTIONS, HIGHLIGHTING THE NEED FOR SAFE AND EFFECTIVE VACCINES TO PREVENT INFLUENZA AIRWAY INFECTIONS IN COWS AND REDUCE SPREAD BETWEEN ANIMALS AND HUMANS. CURRENT INTRAMUSCULAR VACCINES, SUCH AS MRNA VACCINES, ARE HIGHLY EFFECTIVE IN REDUCING SEVERE DISEASES AND DEATHS BUT DO NOT PREVENT RESPIRATORY INFECTIONS AND TRANSMISSION. THIS LIMITATION ARISES BECAUSE INTRAMUSCULAR VACCINES PRIMARILY STIMULATE SYSTEMIC IMMUNITY, WHICH IS INSUFFICIENT FOR PROTECTING THE RESPIRATORY MUCOSA. TO ADDRESS THIS CHALLENGE, DEVELOPING MUCOSAL VACCINES THAT ELICIT LONG-LASTING MUCOSAL IMMUNITY IS ESSENTIAL. THESE VACCINES COULD PREVENT BOTH INITIAL AND RECURRENT INFLUENZA VIRUS INFECTIONS AND THEIR TRANSMISSION. RECENT STUDIES HAVE DEMONSTRATED THAT USING AN FCRN-BASED PLATFORM TO DELIVER INFLUENZA HEMAGGLUTININ (HA) AND SARS-COV-2 SPIKE ANTIGENS THROUGH THE AIRWAY CAN INDUCE PROTECTIVE MUCOSAL IMMUNITY IN BOTH THE NASAL AND LUNG COMPARTMENTS. THIS NASAL VACCINE EFFECTIVELY PREVENTS VIRUS REPLICATION IN ANIMALS AND LIMITS TRANSMISSION AMONG THEM. THESE FINDINGS LED US TO REASON THAT FCRN-MEDIATED NASAL SPRAY VACCINES FOR INFLUENZA CAN TRIGGER RECALL RESPONSES THAT PROTECT AGAINST INITIAL AND RECURRENT H5N1 INFECTIONS IN THE AIRWAY AND REDUCE ANIMAL-TO-ANIMAL AND ANIMAL-TO-HUMAN TRANSMISSION. GIVEN THE RAPIDLY EVOLVING NATURE OF INFLUENZA VIRUSES, WE AIM TO DEVELOP UNIVERSAL MUCOSAL VACCINES. THE VACCINES DELIVERED THROUGH THE FCRN PLATFORM CAN BE EASILY ENGINEERED, MANUFACTURED, AND ADAPTED FOR USE AGAINST OTHER MUCOSAL INFECTIONS IN LIVESTOCK.
$648,881University Of Maryland, College Park · · FY2025 · National Institute of Food and Agriculture
Software for the complete characterization of antibody repertoires: from germline and mRNA sequence assembly to deep learning predictions of their protein structures and targets
$648,790Timothy J Durfee · Dnastar, Inc. · R44 · FY2023 · GM
A Longitudinal Study of COVID-19 Sequelae and Immunity
$648,551Michael C Sneller · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Alaska Native Communities Advancing Vaccine Uptake
$648,487Julie Beans · Southcentral Foundation · R01 · FY2024 · AI
Use of Behavioral Economics in Repeat SARS-CoV-2 Antibody Testing in Disadvantaged Communities
$648,399Jason N Doctor · University Of Southern California · R33 · FY2020 · AG
Improving the Collaborative Health of Minority COVID-19 Survivor & Carepartner Dyads Through Interventions Targeting Social and Structural Health Inequities
$648,398Gayenell Smith Magwood · University Of South Carolina At Columbia · R01 · FY2024 · NR
The longitudinal impact of the COVID-19 pandemic and related multi-level mitigation and contextual factors on health and socioeconomic outcomes of individuals and families from a vulnerable population
$648,317Colter M.s. Mitchell · University Of Michigan At Ann Arbor · U01 · FY2022 · HD
Broad-spectrum therapeutics against SARS-CoV-2 3CL protease
$648,225Raymond F. Schinazi · Emory University · R01 · FY2023 · AI
Evaluating SARS-CoV-2 spike antigen-induced coagulopathy and neuroinflammation as mechanistic drivers of neurologic PASC
$647,609Michael Joseph Peluso · University Of California, San Francisco · R01 · FY2025 · NS
Emergency preparedness and support of caregivers of persons with dementia: The Disaster PrepWise study
$647,252Sato Ashida · University Of Iowa · R01 · FY2022 · AG
Addressing COVID 19 Vaccine Hesitancy in Rural Community Pharmacies Reducing Disparities Through an Implementation Science Approach
$646,833Delesha Miller Carpenter · Univ Of North Carolina Chapel Hill · R01 · FY2023 · MD
Improving Glycemia & Reducing Diabetes Distress in Adolescents & Young Adults with T1D
$646,831Lori M Laffel · Joslin Diabetes Center · R01 · FY2024 · DK
B-cell response and thrombotic complications in COVID-19
$646,675Renren Wen · Versiti Wisconsin, Inc. · R01 · FY2024 · HL
Digital Health and Health Disparities Research Lab
$646,598Sherine El-Toukhy · National Institute On Minority Health And Health Disparities · ZIA · FY2024 · MD
Olfactory mucosa repair and defense: neuro-immune mechanisms and therapy
$646,346Andrew P Lane · Johns Hopkins University · R01 · FY2025 · DC
The effect of SARS-CoV-2 on the susceptibility of respiratory outcomes in a Puerto Rican Birth Cohort
$646,280Dean Sheppard · University Of California, San Francisco · U01 · FY2021 · HL
The Impact of COVID-19 on End-of-Life Care for Vulnerable Populations
$646,188Melissa Diane Aldridge · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · NR
Therapeutic Electrical Stimulation Using Wireless, Resorbable Implants to Accelerate Diaphragm Muscle Reinnervation after Phrenic Neuropathy
$645,644Colin Franz · Rehabilitation Institute Of Chicago D/B/A Shirley Ryan Abilitylab · R01 · FY2025 · NS
Broad-spectrum therapeutics against SARS-CoV-2 3CL protease
$645,603Raymond F. Schinazi · Emory University · R01 · FY2024 · AI